Abstract
Translocator protein (TSPO) is well known inflammatory target. We have designed a new molecule DOTA-MBP. In-silico studies have been performed to evaluate the binding affinity potential of MBP towards the TSPO. The stability of DOTA-MBP was assessed for Gd (III) for possible application as chelating vehicle or other MR contrast agent. For in vivo studies LPS induced lung inflammation model was develop in mice and after 24 h of LPS administration biodistribution and 99mTc-DOTA-MBP imaging have been performed to monitor the uptake and distribution of radioactivity in different peripheral organs with time. In conclusion we can say that DOTA-MBP as potential candidate to locate the lung inflammation as well as monitor the severity of disease through SPECT or MRI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
